Registration Number
0221U104834,
0118U003727
, R & D reports
Title
Identify ways to reduce disability in patients with localized kidney cancer based on the development and optimization of innovative diagnostic methods, neoadjuvant targeted therapy and surgical treatment.
popup.stage_title
Head
Stakhovskyi Eduard O, Доктор медичних наук
Registration Date
25-04-2021
Organization
National Cancer Institute
popup.description2
The object of the study was 167 patients with localized renal cell carcinoma (NCD). Research methods: clinical, laboratory, radiological, functional, pathomorphological, statistical. The developed combined approach to the treatment of patients with localized NKR using neoadjuvant TT led to a statistically significant regression of the tumor by an average of 20.4 ± 14.4 (17.1 - 23.8)%, with a primary tumor size of 61.3 ± 19 , 5 (56.5 - 65.7) mm, which provided the possibility of organ-sparing surgical treatment in 90.3% of cases compared with 48.8% among patients without TT (x2 = 33.9; p <0.001). It was found that the neoadjuvant mode of TT in patients with localized NKR can significantly (χ2 = 4.77; p <0.05) reduce the level of side effects from 63% to 42% compared with adjuvant, due to the greater number of functioning renal parenchyma and higher glomerular filtration rate (Mann-Whitney U test; p <0.005). It was found that the optimal duration of neoadjuvant TT in patients with localized NKR is the use of 2 cycles. Increasing the number of cycles of therapy leads to an increase in the duration and cost of treatment, increasing the number of side effects of TT by 17% in the absence of further regression of NKR, which does not affect the choice of surgery, intraoperative blood loss, duration of surgery and hospitalization (p> 0.05) . In the course of the study it was proved that conducting two blocks of neoadjuvant TT does not affect the level of both total glomerular filtration (t-test; p = 0.57) and renal function on the affected side (t-test; p = 0.84 ), and can be considered safe. Conducting neoadjuvant TT in patients with localized NKR allowed a statistically significant increase in the median volume of the functioning renal parenchyma by 21% (Mann-Whitney U Test; p <0.001), reduce the average tumor size by 11.5 mm (t-test; p <0.001), which allowed to restrict NKR in 38.6% of cases (x2 = 15.5; p <0.001) and played a key role in the choice of treatment.
Product Description
popup.authors
Vitruk Iurii V
Voylenko Oleg А.
Vukalovich Peter S
Havryliuk Oksana M
Kononenko Oleksiy A
Pikulʹ Maksym V
Pilin Yevheniy V
Semko Sofiya L
Stakhovsky Olexander E
popup.nrat_date
2021-04-25
